Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Day One Biopharmaceuticals, Inc. DAWN
$13.23
-$0.46 (-3.47%)
На 18:04, 12 мая 2023
+211.79%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
993230100.00000000
-
week52high
28.35
-
week52low
5.44
-
Revenue
0
-
P/E TTM
-7
-
Beta
0.00000000
-
EPS
-2.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 мая 2023 г. в 09:00
Описание компании
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 21 июн 2022 г. |
| Wedbush | Outperform | Outperform | 14 июн 2022 г. |
| Wedbush | Outperform | 21 июн 2021 г. | |
| Piper Sandler | Overweight | 21 июн 2021 г. | |
| JP Morgan | Overweight | 21 июн 2021 г. | |
| Piper Sandler | Overweight | Overweight | 09 янв 2023 г. |
| HC Wainwright & Co. | Buy | Buy | 09 янв 2023 г. |
| Goldman Sachs | Buy | Buy | 09 янв 2023 г. |
| HC Wainwright & Co. | Buy | 15 дек 2022 г. | |
| Goldman Sachs | Buy | 05 дек 2022 г. | |
| Oppenheimer | Perform | 03 февр 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Grant Julie Papanek | D | 355000 | 1106 | 01 февр 2023 г. |
| Grant Julie Papanek | D | 356106 | 23894 | 01 февр 2023 г. |
| Bender Jeremy | D | 1181486 | 12500 | 23 янв 2023 г. |
| York Charles N II | D | 268810 | 10000 | 20 янв 2023 г. |
| York Charles N II | A | 36000 | 36000 | 17 янв 2023 г. |
| York Charles N II | A | 116000 | 116000 | 17 янв 2023 г. |
| Blackman Samuel C. | A | 23000 | 23000 | 17 янв 2023 г. |
| Blackman Samuel C. | A | 72000 | 72000 | 17 янв 2023 г. |
| Bender Jeremy | A | 76000 | 76000 | 17 янв 2023 г. |
| Bender Jeremy | A | 244000 | 244000 | 17 янв 2023 г. |
Новостная лента
Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
20 дек 2022 г. в 08:00
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time.
Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Seeking Alpha
04 сент 2022 г. в 12:17
Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position.
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
GlobeNewsWire
02 авг 2022 г. в 08:00
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tuesday, August 9 at 10:55 a.m. ET.
Biotech ETF Tops in June: 5 Stocks That Outperform
Zacks Investment Research
30 июн 2022 г. в 14:52
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.
Here's How Day One Biopharmaceuticals Stock Could Keep Climbing
The Motley Fool
15 июн 2022 г. в 05:41
A giant run-up on Monday could be the beginning of a much larger bull run.